Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1975 Apr;55(4):754–762. doi: 10.1172/JCI107986

Somatostatin blockade of acute and chronic stimuli of the endocrine pancreas and the consequences of this blockade on glucose homeostasis.

E W Chideckel, J Palmer, D J Koerker, J Ensinck, M B Davidson, C J Goodner
PMCID: PMC301812  PMID: 804491

Abstract

The nature and extent of somatostatin-induced inhibition of pancreatic endocrine secretion were studied by administration of a number of stimuli of either glucagon or insulin to over night fasted baboons with and without an infusion of linear somatostatin. The stimuli for acute-phase insulin release were intravenous pulses of glucose, tolbutamide, isoproterenol, and secretin. When given 15 min after the start of a somatostatin infusion, these agents were essentially unable to stimulate insulin secretion. Chronic insulin secretion was stimulated by infusions of either glucose or glucagon. Within 10 min of the start of a super-imposed infusion of somatostatin, insulin levels fell to less than 40 percent of prestimulus control and remained suppressed for the duration of the somatostatin infusion. Stimulation of glucagon secretion by insulin-induced hypoglycemia was also blocked by somatostatin. Plasma glucose decreased during somatostatin infusions except when superimposed upon an infusion of glucagon. Somatostatin had no effect on glucose production in a rat liver slice preparation. We conclude: (a) Somatostatin is a potent and so far universally effective inhibitor of both acute and chronic phases of stimulated insulin and glucagon secretion (b) The inhibitory effect is quickly reversible and the pattern of recovery of secretion is appropriate to prevailing signals; (c) Present evidence suggests that the effect of somatostatin on blood glucose is mediated through its effect on blood glucagon; (d) In the overnight-fasted baboon both in the basal state and 45 min into a 4-mg/kg-min glucose infusion, a somatostatin-induced fall in serum insulin levels appears to be unable to prevent a decrease in hepatic glucose production.

Full text

PDF
754

Images in this article

756Image
on p.756
756Image
on p.756
757Image
on p.757
757Image
on p.757
758Image
on p.758
758Image
on p.758
759Image
on p.759

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti K. G., Christensen N. J., Christensen S. E., Hansen A. P., Iversen J., Lundbaek K., Seyer-Hansen K., Orskov H. Inhibition of insulin secretion by somatostatin. Lancet. 1973 Dec 8;2(7841):1299–1301. doi: 10.1016/s0140-6736(73)92873-0. [DOI] [PubMed] [Google Scholar]
  2. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(4068):77–79. doi: 10.1126/science.179.4068.77. [DOI] [PubMed] [Google Scholar]
  3. Conway M. J., Goodner C. J., Werrbach J. H., Gale C. C. Studies of substrate regulation in fasting. II. Effect of infusion of glucose io the carotid artery upon fasting lipolysis in the baboon. J Clin Invest. 1969 Aug;48(8):1349–1362. doi: 10.1172/JCI106101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coore H. G., Randle P. J. Regulation of insulin secretion studied with pieces of rabbit pancreas incubated in vitro. Biochem J. 1964 Oct;93(1):66–78. doi: 10.1042/bj0930066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davidson M. B., Aoki V. S. Fasting glucose homeostasis in rats after chronic exposure to hypoxia. Am J Physiol. 1970 Aug;219(2):378–383. doi: 10.1152/ajplegacy.1970.219.2.378. [DOI] [PubMed] [Google Scholar]
  6. Davidson M. B., Berliner J. A. Acute effects of insulin on carbohydrate metabolism in rat liver slices: independence from glucagon. Am J Physiol. 1974 Jul;227(1):79–87. doi: 10.1152/ajplegacy.1974.227.1.79. [DOI] [PubMed] [Google Scholar]
  7. Ensinck J. W., Shepard C., Dudl R. J., Williams R. H. Use of benzamidine as a proteolytic inhibitor in the radioimmunoassay of glucagon in plasma. J Clin Endocrinol Metab. 1972 Sep;35(3):463–467. doi: 10.1210/jcem-35-3-463. [DOI] [PubMed] [Google Scholar]
  8. Feldman J. M., Lebovitz H. E. Ammonium ion, a modulator of insulin secretion. Am J Physiol. 1971 Oct;221(4):1027–1032. doi: 10.1152/ajplegacy.1971.221.4.1027. [DOI] [PubMed] [Google Scholar]
  9. Feldman J. M., Lebovitz H. E. Specificity of serotonin inhibition of insulin release from golden hamster pancreas. Diabetes. 1970 Jul;19(7):475–479. doi: 10.2337/diab.19.7.475. [DOI] [PubMed] [Google Scholar]
  10. Goldsmith S. J., Yalow R. S., Berson S. A. Effects of 2-deoxy-D-glucose on insulin-secretory responses to intravenous glucose, glucagon, tolbutamide and arginine in man. Diabetes. 1970 Jun;19(6):453–457. doi: 10.2337/diab.19.6.453. [DOI] [PubMed] [Google Scholar]
  11. Hall R., Besser G. M., Schally A. V., Coy D. H., Evered D., Goldie D. J., Kastin A. J., McNeilly A. S., Mortimer C. H., Phenekos C. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet. 1973 Sep 15;2(7829):581–584. doi: 10.1016/s0140-6736(73)92413-6. [DOI] [PubMed] [Google Scholar]
  12. Kizer J. S., Vargas-Gordon M., Brendel K., Bressler R. The in vitro inhibition of insulin secretion by diphenylhydantoin. J Clin Invest. 1970 Oct;49(10):1942–1948. doi: 10.1172/JCI106413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Koerker D. J., Ruch W., Chideckel E., Palmer J., Goodner C. J., Ensinck J., Gale C. C. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science. 1974 Apr 26;184(4135):482–484. doi: 10.1126/science.184.4135.482. [DOI] [PubMed] [Google Scholar]
  14. Lerner R. L., Porte D., Jr Studies of secretin-stimulated insulin responses in man. J Clin Invest. 1972 Aug;51(8):2205–2210. doi: 10.1172/JCI107028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lev-Ran A., Laor J., Vins M., Simon E. Effect of intravenous infusion of D-mannoheptulose on blood glucose and insulin levels in man. J Endocrinol. 1970 May;47(1):137–138. doi: 10.1677/joe.0.0470137. [DOI] [PubMed] [Google Scholar]
  16. MURPHY B. E., PATTEE C. J. DETERMINATION OF PLASMA CORTICOIDS BY COMPETITIVE PROTEIN-BINDING ANALYSIS USING GEL FILTRATION. J Clin Endocrinol Metab. 1964 Sep;24:919–923. doi: 10.1210/jcem-24-9-919. [DOI] [PubMed] [Google Scholar]
  17. Malherbe C., Burrill K. C., Levin S. R., Karam J. H., Forsham P. H. Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med. 1972 Feb 17;286(7):339–342. doi: 10.1056/NEJM197202172860702. [DOI] [PubMed] [Google Scholar]
  18. Mortimer C. H., Tunbridge W. M., Carr D., Yeomans L., Lind T., Coy D. H., Bloom S. R., Kastin A., Mallinson C. N., Besser G. M. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet. 1974 Apr 20;1(7860):697–701. doi: 10.1016/s0140-6736(74)92903-1. [DOI] [PubMed] [Google Scholar]
  19. Nonaka K., Foà P. P. A simplified glucagon immunoassay and its use in a study of incubated pancreatic islets. Proc Soc Exp Biol Med. 1969 Jan;130(1):330–336. doi: 10.3181/00379727-130-33549. [DOI] [PubMed] [Google Scholar]
  20. Porte D., Jr, Graber A. L., Kuzuya T., Williams R. H. The effect of epinephrine on immunoreactive insulin levels in man. J Clin Invest. 1966 Feb;45(2):228–236. doi: 10.1172/JCI105335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rees L. H., Cook D. M., Kendall J. W., Allen C. F., Kramer R. M., Ratcliffe J. G., Knight R. A. A radioimmunoassay for rat plasma ACTH. Endocrinology. 1971 Jul;89(1):254–261. doi: 10.1210/endo-89-1-254. [DOI] [PubMed] [Google Scholar]
  22. Santeusanio F., Faloona G. R., Unger R. H. Suppressive effect of secretin upon pancreatic alpha cell function. J Clin Invest. 1972 Jul;51(7):1743–1749. doi: 10.1172/JCI106975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Seyffert W. A., Jr, Madison L. L. Physiologic effects of metabolic fuels on carbohydrate metabolism. I. Acute effect of elevation of plasma free fatty acids on hepatic glucose output, peripheral glucose utilization, serum insulin, and plasma glucagon levels. Diabetes. 1967 Nov;16(11):765–776. doi: 10.2337/diab.16.11.765. [DOI] [PubMed] [Google Scholar]
  24. Siler T. M., VandenBerg G., Yen S. S., Brazeau P., Vale W., Guillemin R. Inhibition of growth hormone release in humans by somatostatin. J Clin Endocrinol Metab. 1973 Oct;37(4):632–634. doi: 10.1210/jcem-37-4-632. [DOI] [PubMed] [Google Scholar]
  25. UNGER R. H., EISENTRAUT A. M., McCALL M. S., MADISON L. L. Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. J Clin Invest. 1962 Apr;41:682–689. doi: 10.1172/JCI104525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. WOLFF F. DIAZOXIDE HYPERGLYCAEMIA AND ITS CONTINUED RELIEF BY TOLBUTAMIDE. Lancet. 1964 Feb 8;1(7328):309–310. doi: 10.1016/s0140-6736(64)92414-6. [DOI] [PubMed] [Google Scholar]
  27. Werrbach J. H., Gale C. C., Goodner C. J., Conway M. J. Effects of autonomic blocking agents on growth hormone, insulin, free fatty acids and glucose in baboons. Endocrinology. 1970 Jan;86(1):77–82. doi: 10.1210/endo-86-1-77. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES